Mecobalamin - Eisai

Drug Profile

Mecobalamin - Eisai

Alternative Names: E 0302

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Class Vitamin B12 analogues; Vitamins
  • Mechanism of Action Methyltransferase stimulants; Vitamin B12 receptor protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 02 Aug 2017 Discontinued - Preregistration for Amyotrophic lateral sclerosis in Japan (IM), because mecobalamin was not listed on Eisai pipeline of August 2017
  • 31 Mar 2017 Eisai completes a phase II/III extension trial for Amyotrophic lateral sclerosis in Japan (IM) (NCT00445172)
  • 22 Mar 2016 Eisai withdraws NDA for Amyotrophic lateral sclerosis (ALS) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top